The Importance Of Early Manufacturing Choices And Simple Flexible Process Design

In this first segment of Cell & Gene Live, Designing Early Manufacturing For Long-Term Success In CGT, Raymond Luke, Senior Director of MSAT at Verismo Therapeutics and Todd Luman, Executive Director of Process and Product Development at Allogene explore how early manufacturing decisions influence long-term success in cell therapy development. Luman emphasizes the importance of viewing cell and gene therapy through a single-cycle development lens, noting that early, thoughtful investment in process design pays off later when comparability challenges limit major changes. Luke shares that in autologous therapy development, processes should start simple, flexible, and data-driven, allowing room for innovation without adding unnecessary complexity.